Shares of Indivior PLC (LON:INDV – Get Free Report) dropped 21.3% during mid-day trading on Thursday . The stock traded as low as GBX 548.71 ($6.93) and last traded at GBX 683 ($8.63). Approximately 1,971,282 shares traded hands during mid-day trading, an increase of 177% from the average daily volume of 711,780 shares. The stock had previously closed at GBX 868 ($10.97).
Analysts Set New Price Targets
Separately, Jefferies Financial Group restated a “buy” rating and issued a GBX 1,800 ($22.74) target price on shares of Indivior in a report on Tuesday, December 17th.
Check Out Our Latest Research Report on Indivior
Indivior Trading Down 5.9 %
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- Why Invest in High-Yield Dividend Stocks?
- DuPont’s Electronics Spinoff: The Start of Something Big
- Investing in the High PE Growth Stocks
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
- What is a Death Cross in Stocks?
- Market Shift: These 3 Stocks Are Winning While Big Tech Lags
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.